Skip to main content
SpringerLink
Log in

Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial

  • Letter to the Editor
  • Published:
World Journal of Urology Aims and scope

The Original Article was published on 02 March 2024

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Wada N, Mizunaga M, Abe N et al (2024) Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World J Urol 42:113. https://doi.org/10.1007/s00345-024-04799-4

    Article  CAS  PubMed  Google Scholar 

  2. Farag F, Sakalis VI, Arteaga SM et al (2023) What are the short-term benefits and potential harms of therapeutic modalities for the management of overactive bladder syndrome in women? A review of evidence under the auspices of the european association of urology, female non-neurogenic lower urinary tract symptoms guidelines panel. Eur Urol 84:302–312. https://doi.org/10.1016/j.eururo.2023.05.014

    Article  CAS  PubMed  Google Scholar 

  3. Tarcan T, Selai C, Herve F et al (2020) Should we routinely assess psychological morbidities in idiopathic lower urinary tract dysfunction: ICI-RS 2019? Neurourol Urodyn 39:S70–S79. https://doi.org/10.1002/nau.24361

    Article  PubMed  Google Scholar 

  4. Kinjo M, Masuda K, Nakamura Y et al (2023) Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study. Urology 175:67–73. https://doi.org/10.1016/j.urology.2023.02.003

    Article  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Chengdu Center for Disease Control and Prevention, Chengdu, 610041, China

    Rong Dai

  2. Department of Pediatric Surgery, School of Medicine, Chengdu Women’s and Children’s Central Hospital, University of Electronic Science and Technology of China, Chengdu, 611731, China

    Changkai Deng

Authors
  1. Rong Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Changkai Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Author contributions CD Project development, management, data analysis, manuscript writing. RD Data collection, manuscript writing.

Corresponding author

Correspondence to Changkai Deng.

Ethics declarations

Conflict of interest

Author Changkai Deng declares that he has no confict of interest. Author Rong Dai declares that she has no confict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dai, R., Deng, C. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World J Urol 42, 316 (2024). https://doi.org/10.1007/s00345-024-05025-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00345-024-05025-x

Search

Navigation